Role of G-protein coupled receptor (GPCRs)/(GPR-120) as an agonists in diabetic wound healing

Abstract

Type 2 diabetes (T2D) or Obesity has been gradually rising throughout the globe. It is a major cause of noncommunicable illnesses such as cardiovascular disease type 2 diabetes (T2D), Nonalcoholic Steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and numerous malignancies, all of which have a negative effect on quality of natural life and life expectancy. Diabetic wound healing is hampered by a complicated pathophysiology combining immunological, metabolic factors and neuropathic. There are more than thirty GPCRs that have been occupied in the expansion or development of β-cell disfunction, insulin resistance, obesity, and T2DM Still, at current, only the GLP-1R has been effectively battered therapeutically. They play major function in gut hormone Secretion and appetite control adipogenesis, anti-inflammatory functions, antidiabetic functions. Diabeties is current treated by dressings, antidiabetic Drugs, growth factors such as (TGF1, FGF, EGF, VEGF and PDGF). Future therapeutic strategies will be based on single growth factor, multiple growth factor, skin, cytokine enhancer, cytokine antagonist, matrix metalloproteinase antagonist, gene therapy and stem cell therapy, extracellular matrix and angiogenesis. • GPCRs, transmit their signals mostly via the alpha subunits and Ga12/13, Gai/o, Gas, and Gaq/11, are the four main functional characteristics of their alpha subunits. • GPCRs, as indicated in the genesis or evolution of – insulin resistance, obesity and cell dysfunction, encouraged (T2DM). • GPCRs including as GPR65, GPR4, GPR132, and GPR68, are implicated in wound healing. • GPR120 is strongly stated in enteroendocrine cells, which promotes stomach inhibitory peptide production (GIP) and engaged in a well-coordinated anti-diabetic action.